Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Table 1 Incidence of neuropathy in statin user and non-user group

				Propensity score-matched1
	Statin user, n (%)	Statin non-user, n (%)	P value	Statin user, n (%)	Statin non-user, n (%)	P value
2016
Neuropathy incidence	582/17413 (3.34)	477/17267 (2.76)	0.0017	579/17267 (3.35)	477/17267 (2.76)	0.0014
2017
Neuropathy incidence	562/18707 (3.00)	449/16882 (2.66)	0.0507	523/16882 (3.10)	449/16882 (2.66)	0.0160

¹Propensity score-matching was performed by including baseline age, gender and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS).